MUC1 antibodies, CA 15-3 and CA 27-29, have been developed and used to detect recurrent breast cancer, monitoring the treatment of patients with advanced breast cancer and as a prognostic marker [15–17]. This evidence concerns the gene MUC1 and breast cancer.